MINNEAPOLIS, Oct. 27 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq :UPI ), announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued a guidance document titled "Percutaneous Posterior Tibial Nerve Stimulation for Overactive Bladder Syndrome," reinforcing the safety and effectiveness of PTNS for overactive bladder.
"The significance of this guidance in the U.K. is a positive statement affirming the evidence that PTNS is efficacious in reducing the symptoms of overactive bladder and there are no major safety concerns," said David Kaysen, President and CEO of Uroplasty. "We will help medical directors of U.S. private payers and Medicare carriers understand this guidance and its significance as we continue to meet with them to expand coverage for our Urgent® PC Neuromodulation System in the United States."
In the U.K., NICE makes recommendations to the country's National Health Service (NHS) on new and existing medicines, treatments and procedures with the goal of improving health and treating and preventing poor health. A copy of the NICE guidance may be found at www.nice.org.uk.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.
We also offer Macroplastique Implants®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements, that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, regulatory changes, including a scheduled but deferred across-the-board reduction in Medicare reimbursement, could impact the reimbursement received for use of our products, we may not be able to convince all or most of the agencies that administer government programs, or private payers, to reimburse based on the new code, we cannot be certain that our expenditures to expand our sales force will be justified by increased sales, and we cannot be certain that larger competitors will not introduce products or pharmaceuticals that target the portion of the market for which Urgent PC is designed.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
Doug Sherk (Investors)
Chris Gale (Media)
CPT is a registered trademark of the American Medical Association
SOURCE Uroplasty, Inc.